For the last few years, Ozempic and Wegovy have mostly been a weight loss story. Doctors are now looking at something else these drugs might do, something that has nothing to do with weightloss, and something that could matter someday (not yet) to anyone working through drug and alcohol addiction treatment.
What’s Going On in the Brain
Researchers have been tracing this effect to a part of the brain called the lateral septum, a region packed with GLP-1 receptors, the same receptors these medications target. The lateral septum sits at a kind of junction point, linking memory and surroundings to the feeling of wanting something. It’s the part of your brain that turns “I remember how good that felt” into “I want that right now.” A study out of the University of Gothenburg found that activating GLP-1 receptors specifically in this region reduced alcohol’s rewarding effects in rodents and cut alcohol intake without touching how much they ate or drank water. Blocking those same receptors did the opposite and increased drinking. That’s a real mechanistic finding. But will any effect be found in humans?
What the Human Studies Show
Animal studies are one thing. People are another, and there’s now real human data too. A study out of the University of Colorado gave people who drank moderately to heavily either oral semaglutide or a placebo. The group on semaglutide cut their heavy drinking days by 41 percent, compared to a 26 percent reduction in the placebo group. One of the researchers, Schacht, made a point worth sitting with: most people with alcohol use disorder don’t actually want to be completely abstinent, they want their drinking to stop running their life. A medication that turns the volume down on craving without demanding total abstinence is a genuinely different tool than most of what currently exists.
Other recent trials have found similar things, reduced cravings, fewer heavy drinking days, though results across studies haven’t been perfectly consistent. That’s normal for a treatment this early in its research life, not a red flag.
Don’t Get Ahead of the Research
Here’s where we’d rather be careful than exciting. Semaglutide is not FDA-approved for alcohol or substance use disorder (Not even close or seeking approval either). The medications currently FDA-approved for alcohol use disorder are naltrexone, acamprosate, and disulfiram, and that is it. What’s happening with GLP-1 drugs is promising early research, not an established treatment, and definitely not something to start or stop on your own based on a headline.
It’s also not a withdrawal treatment. Reducing a craving over time is a completely different thing from safely managing withdrawal from alcohol or opioids, which can be medically dangerous without supervision. Nothing about this research changes that.
Why We’re Paying Attention Anyway
We follow this kind of research because the field genuinely needs more tools, not because we’re ready to hand out prescriptions based on a study that’s still many years from changing standard practice. If you’re already on a GLP-1 medication for diabetes or weight loss and you’ve noticed your drinking or drug use has changed without trying, that’s worth mentioning to your doctor, not something to keep to yourself.
If cravings are the thing running your life right now, today, the answer isn’t waiting a few years for a new medication to get approved. Florida Springs Wellness and Recovery Center is in Panama City, and we can talk through what’s actually available to you right now for drug and alcohol rehab options in Florida.
